AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm

AstraZeneca Plc said on Tuesday it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as $276 million.

Source: Reuters: Health - October 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news